LYNDHURST, N.J., Sept. 6 /PRNewswire-FirstCall/ -- Quest Diagnostics
Incorporated (NYSE: DGX), the nation's leading provider of diagnostic testing,
information and services, announced that it is scheduled to speak at the
Thomas Weisel Partners Healthcare Conference on Thursday, September 7, 2006,
at the Four Seasons Boston in Boston, Massachusetts. The Quest Diagnostics
presentation is scheduled to begin at 2:05 p.m. Eastern Time.
During the conference, the company will reiterate its 2006 guidance.
Excluding the performance of NID, its test kit manufacturing subsidiary, whose
operations are being discontinued, the company expects revenue growth of
approximately 15%, operating income to approximate 17.5% of revenues, and
earnings per diluted share between $2.95 and $3.05.
The presentation will be webcast live during the conference and will be
available to registered investors on the following site:
http://www.veracast.com/webcasts/twp/healthcare06/82210105.cfm and to the
public on http://www.questdiagnostics.com. In addition, the archived webcast
will be available one hour after the live presentation and will remain
available until October 7, 2006.
Quest Diagnostics is the leading provider of diagnostic testing,
information and services that patients and doctors need to make better
healthcare decisions. The company offers the broadest access to diagnostic
testing services through its national network of laboratories and patient
service centers, and provides interpretive consultation through its extensive
medical and scientific staff. Quest Diagnostics is a pioneer in developing
innovative new diagnostic tests and advanced healthcare information technology
solutions that help improve patient care. Additional company information is
available at: www.questdiagnostics.com.
The statements in this press release which are not historical facts or
information may be forward-looking statements. These forward-looking
statements involve risks and uncertainties that could cause actual results and
outcomes to be materially different. Certain of these risks and uncertainties
may include, but are not limited to, competitive environment, changes in
government regulations, changing relationships with customers, payers,
suppliers and strategic partners and other factors described in the Quest
Diagnostics Incorporated 2005 Form 10-K and subsequent SEC filings.
SOURCE Quest Diagnostics Incorporated
CONTACT: Laure Park, Investors, +1-201-393-5030, or Gary Samuels, Media,
+1-201-393-5700, both of Quest Diagnostics Incorporated
Web site: http://www.questdiagnostics.com